Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Waters (WAT – Research Report) and Beam Therapeutics (BEAM – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Waters (WAT)
In a report released today, Matt Larew from William Blair maintained a Buy rating on Waters. The company’s shares closed last Friday at $381.29.
According to TipRanks.com, Larew is a 1-star analyst with an average return of
Currently, the analyst consensus on Waters is a Moderate Buy with an average price target of $437.25, representing a 15.9% upside. In a report issued on January 27, HSBC also initiated coverage with a Buy rating on the stock with a $460.00 price target.
See the top stocks recommended by analysts >>
Beam Therapeutics (BEAM)
In a report released today, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics. The company’s shares closed last Friday at $26.52.
According to TipRanks.com, Corwin is a 5-star analyst with an average return of
Currently, the analyst consensus on Beam Therapeutics is a Strong Buy with an average price target of $48.56.
